产品
编 号：F285528
分子式：C21H31N5O2
分子量：385.5
分子式：C21H31N5O2
分子量：385.5
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 2328073-61-4
产品详情
生物活性：
ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM.
体内研究：
ZT-12-037-01 (腹腔注射；25-50 mg/kg；每日一次；21 天) 抑制 SK-MEL-2 异种移植黑色素瘤的生长，肿瘤切片表明通过增加裂解的 caspase-3 诱导细胞凋亡。Animal Model:SK-MEL-2 xenograft melanoma nude mice with hTERT/p53DD/CDK4(R24C) melanocytes
Dosage:25 mg/kg; 50 mg/kg
Administration:Intraperitoneally injection; 21 days; once a day
Result:Inhibited growth of SK-MEL-2 xenograft melanoma.
体外研究：
ZT-12-037-01 (3 μM；14 天) 显著抑制突变的 NRAS-STK19 驱动的黑色素细胞集落形成和增殖。 ZT-12-037-01 (0-3 μM) 具有 ZT-12-037-01 对HPMs中STK19WT和STK19D89N激活的NRAS磷酸化的抑制作用。
ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM.
体内研究：
ZT-12-037-01 (腹腔注射；25-50 mg/kg；每日一次；21 天) 抑制 SK-MEL-2 异种移植黑色素瘤的生长，肿瘤切片表明通过增加裂解的 caspase-3 诱导细胞凋亡。Animal Model:SK-MEL-2 xenograft melanoma nude mice with hTERT/p53DD/CDK4(R24C) melanocytes
Dosage:25 mg/kg; 50 mg/kg
Administration:Intraperitoneally injection; 21 days; once a day
Result:Inhibited growth of SK-MEL-2 xenograft melanoma.
体外研究：
ZT-12-037-01 (3 μM；14 天) 显著抑制突变的 NRAS-STK19 驱动的黑色素细胞集落形成和增殖。 ZT-12-037-01 (0-3 μM) 具有 ZT-12-037-01 对HPMs中STK19WT和STK19D89N激活的NRAS磷酸化的抑制作用。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备